Nicotinamide Riboside Supplementation in Chronic Kidney Disease

What Was Tested

This registered phase 2 trial tested NAD+.

This study is testing whether a dietary supplement called nicotinamide riboside, (NR), can be used in adults with moderate chronic kidney disease.

NR is a form of vitamin B3 that may help support cellular energy metabolism.

The main goal of this study is to see whether it is feasible for people with chronic kidney disease to take NR daily, complete study visits, and follow the study procedures.

It had two arms (groups): Placebo Then NR (experimental) and NR Then Placebo (experimental).

The registry classes the interventions as dietary supplement.

More on the Plan

Nicotinamide riboside is a vitamin B3 derivative and NAD+ precursor that may support cellular energy metabolism and vascular health.

This pilot study will evaluate the feasibility of using nicotinamide riboside in adults with moderate chronic kidney disease.

The study uses a randomized, double-blind, placebo-controlled crossover design so that each participant receives both nicotinamide riboside chloride and placebo during separate treatment periods.

In addition to feasibility measures, the study will collect exploratory data on mitochondrial, microvascular, and physical function outcomes.

Who Took Part

The registry lists 30 planned participants were the target.

It was open to people of any sex aged from 30 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Able to provide informed consent. Able to walk unassisted from room to room, with usual assistive device allowed if approved by study safety assessment. Willing and able to comply with study procedures, visits, and study product administration.

The full record lists 5 inclusion and 12 exclusion criteria; among the exclusions: expectation to start dialysis within 6 months; unable to walk unassisted from room to room; institutionalization or inability to consent.

How the Study Was Run

The set-up was randomized, crossover and triple-blind.

The participants were allocated by chance, so the NAD+ group and the comparison group should start out alike.

In the crossover set-up each of the participants took both NAD+ and the comparison in turn, acting as their own control.

Blinding on both sides kept the participants and researchers unaware of who received NAD+.

Those kept unaware of assignments: participant, investigator and outcomes assessor.

It started in 2026-10-01 with completion listed for 2028-09-30.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Change in plasma cell-free mitochondrial DNA (time frame: Baseline, Week 12, and Week 26). Change in urine cell-free mitochondrial DNA (time frame: Baseline, Week 12, and Week 26).

It also tracked 6 secondary outcomes, for example Change in skin fingernail capillary density, Change in skin blood flow, Change in six-minute walk distance, Change in Handgrip Strength, Change in Timed Up and Go and Change in 30-second sit-to-stand.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of NAD+ in 30 people.

Its size is small, so on its own it can only give an early look.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.